Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern

Haematologica

Volumn 100, Issue 7, 2015, Pages e275-e279

  Ferreiro, Julio Finalet ^a   Morscio, Julie ^a   Dierickx, Daan ^b   Marcelis, Lukas ^a   Verhoef, Gregor ^b   Vandenberghe, Peter ^a   Tousseyn, Thomas ^a   Wlodarska, Iwona ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Burkitt lymphoma; Post transplant lymphoproliferative disease; PTLD

Indexed keywords

ANTIMETABOLITE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; MYC PROTEIN; PREDNISONE; VINCRISTINE; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTINEOPLASTIC AGENT; ETS1 PROTEIN, HUMAN; FLI1 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; MYC PROTEIN, HUMAN; PAFAH1B2 PROTEIN, HUMAN; RITUXIMAB; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR FLI 1;

B CELL LYMPHOMA; BURKITT LYMPHOMA; CHROMOSOME 11Q; CHROMOSOME 7; CYTOGENETICS; GENE; GENE EXPRESSION; HUMAN; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LYMPHOPROLIFERATIVE DISEASE; MGR GENE; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; PLASMACYTOMA; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; B LYMPHOCYTE; CHROMOSOME 11; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENE TRANSLOCATION; GENETICS; HEART TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CHROMOSOMES, HUMAN, PAIR 11; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MUTATION; PREDNISONE; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEIN C-FLI-1; PROTO-ONCOGENE PROTEINS C-MYC; RITUXIMAB; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; VINCRISTINE;

EID: 84936128409     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.124305     Document Type: Letter

References (14)

1. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354(23):2431-2442.
2. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-2430.
3. Salaverria I, Martin-Guerrero I, Wagener R, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative highgrade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014;123(8):1187-1198.
4. Dierickx D, Tousseyn T, Sagaert X, et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma. 2013;54(11):2433-2440.
5. Morscio J, Dierickx D, Ferreiro JF, et al. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 2013; 13(5):1305-1316.
6. Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and metaanalysis of 277 reported cases. Am J Surg Pathol. 2014;38(7):875-886.
7. Herreman A, Dierickx D, Morscio J, et al. Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Leuk Lymphoma. 2013;54(10):2190-2199.
8. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer, 2008.
9. Pienkowska-Grela B, Rymkiewicz G, Grygalewicz B, et al. Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement. Med Oncol. 2011;28(4):1589-1595.
10. Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012;31(19):2373-2388.
11. Chisholm KM, Bangs CD, Bacchi CE, Kirsch HM, Cherry A, Natkunam Y. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol. 2015;39(3):294-303.
12. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371(11):1005-1015.
13. Finalet FJ, Rouhigharabaei L, Urbankova H, et al. Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. PLoS One. 2014;9(7):e102977.
14. Piccaluga PP, De FG, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood. 2011;117(13):3596-3608.